Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, ...
Eli Lilly secured federal approval for Emgality, the first migraine treatment approved in the U.S. for decreasing the frequency of episodic cluster headache attacks, the FDA announced June 4. 1.
The healthcare bellwether’s performance has been mixed, with the company exceeding earnings expectations in three of the trailing four quarters. It delivered a four-quarter earnings surprise of 8.47%, ...
The healthcare bellwether’s performance has been mixed, with the company exceeding earnings expectations in three of the trailing four quarters. It delivered a four-quarter earnings surprise of 8.47%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback